Rimegepant
Rimegepant is a medication belonging to the class of calcitonin gene-related peptide (CGRP) receptor antagonists. It is primarily used for the treatment of acute migraine attacks in adults.Rimegepant is indicated for the acute treatment of migraine with or without aura in adults.
The recommended dosage of rimegepant is 75 mg taken orally as needed for the treatment of migraine attacks. A second dose may be taken after at least 48 hours if needed.
Rimegepant is contraindicated in patients with a history of hypersensitivity to rimegepant or any of its components.
Caution should be exercised when administering rimegepant to patients with severe hepatic impairment. Additionally, patients with a history of cardiovascular disease should be monitored closely while using rimegepant.
Common side effects of rimegepant may include nausea, fatigue, and dry mouth. Rare but serious side effects may include allergic reactions, cardiovascular events, and hepatotoxicity.
Rimegepant may interact with strong inhibitors or inducers of cytochrome P450 (CYP) 3A4, potentially altering its metabolism and efficacy. Concomitant use of rimegepant with other medications metabolized by CYP3A4 should be monitored closely.
